Clene Inc. (CLNN) stock
CLNNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.92−0.08 (-2.00%)
Close on Nov 13, 2026Market cap $50.37MP/E –Yield –
Clene r&d expenses
Research and development expenses are spending on new products and technology.
Clene's R&D Expenses for the twelve months ending Sep 30, 2026 was $13.75M, down 2.3% year over year. For fiscal 2025 it was $14.01M, down 30.1% from the year before. The highest annual figure on record is $31.92M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.01M | -30.1% |
| FY2024 | Dec 31, 2024 | $20.06M | -24.7% |
| FY2023 | Dec 31, 2023 | $26.66M | -16.5% |
| FY2022 | Dec 31, 2022 | $31.92M | +12.3% |
| FY2021 | Dec 31, 2021 | $28.42M | +86.9% |
| FY2020 | Dec 31, 2020 | $15.20M | +59.0% |
| FY2019 | Dec 31, 2019 | $9.56M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $4.45M | +26.6% |
| Q2 FY2026 | Jun 30, 2026 | $3.47M | -1.2% |
| Q1 FY2026 | Mar 31, 2026 | $329.00K | -77.8% |
| Q4 FY2025 | Dec 31, 2025 | $5.50M | -1.2% |
| Q3 FY2025 | Sep 30, 2025 | $3.51M | -21.4% |
| Q2 FY2025 | Jun 30, 2025 | $3.51M | -15.3% |
| Q1 FY2025 | Mar 31, 2025 | $1.48M | -74.8% |
| Q4 FY2024 | Dec 31, 2024 | $5.57M | -16.6% |
| Q3 FY2024 | Sep 30, 2024 | $4.47M | -25.1% |
| Q2 FY2024 | Jun 30, 2024 | $4.15M | -37.3% |
| Q1 FY2024 | Mar 31, 2024 | $5.87M | -20.6% |
| Q4 FY2023 | Dec 31, 2023 | $6.67M | -27.2% |
| Q3 FY2023 | Sep 30, 2023 | $5.97M | -30.4% |
| Q2 FY2023 | Jun 30, 2023 | $6.62M | -30.5% |
| Q1 FY2023 | Mar 31, 2023 | $7.40M | +20.3% |
| Q2 FY2022 | Jun 30, 2022 | $9.17M | +41.6% |
| Q1 FY2022 | Mar 31, 2022 | $8.58M | +36.7% |
| Q4 FY2021 | Dec 31, 2021 | $9.52M | +113.8% |
| Q3 FY2021 | Sep 30, 2021 | $6.15M | +53.9% |
| Q2 FY2021 | Jun 30, 2021 | $6.47M | +82.1% |
| Q1 FY2021 | Mar 31, 2021 | $6.28M | +96.0% |
| Q4 FY2020 | Dec 31, 2020 | $4.45M | – |
| Q3 FY2020 | Sep 30, 2020 | $3.99M | – |
| Q2 FY2020 | Jun 30, 2020 | $3.55M | – |
| Q1 FY2020 | Mar 31, 2020 | $3.20M | – |
See a number that looks wrong?